These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38031005)

  • 21. Adherence to cysteamine in nephropathic cystinosis: A unique electronic monitoring experience for a better understanding. A prospective cohort study: CrYSTobs.
    Gaillard S; Roche L; Lemoine S; Deschênes G; Morin D; Vianey-Saban C; Acquaviva-Bourdain C; Ranchin B; Bacchetta J; Kassai B; Nony P; Bodénan E; Laudy V; Rouges C; Zarrabian S; Subtil F; Mercier C; Cochat P; Bertholet-Thomas A
    Pediatr Nephrol; 2021 Mar; 36(3):581-589. PubMed ID: 32901297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults.
    Brodin-Sartorius A; Tête MJ; Niaudet P; Antignac C; Guest G; Ottolenghi C; Charbit M; Moyse D; Legendre C; Lesavre P; Cochat P; Servais A
    Kidney Int; 2012 Jan; 81(2):179-89. PubMed ID: 21900880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological treatment of nephropathic cystinosis with cysteamine.
    Kleta R; Gahl WA
    Expert Opin Pharmacother; 2004 Nov; 5(11):2255-62. PubMed ID: 15500372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis.
    Medic G; van der Weijden M; Karabis A; Hemels M
    Curr Med Res Opin; 2017 Nov; 33(11):2065-2076. PubMed ID: 28692321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Negligible urinary cysteamine loss in cystinosis patients with Fanconi syndrome.
    Levtchenko EN; de Graaf-Hess A; Blom HJ; Monnens LA
    Clin Nephrol; 2002 May; 57(5):349-51. PubMed ID: 12036193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nephropathic cystinosis in Poland: a 40-year retrospective study.
    Sikora P; Grenda R; Kowalczyk M; Kieć-Wilk B; Bieniaś B; Rubik J; Szymczak M; Nosek H; Surowiec P; Marquardt T; Beck BB; Zaniew M
    Pol Arch Intern Med; 2022 Nov; 132(11):. PubMed ID: 35997069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppository formulations as a potential treatment for nephropathic cystinosis.
    Buchan B; Kay G; Matthews KH; Cairns D
    J Pharm Sci; 2012 Oct; 101(10):3729-38. PubMed ID: 22778070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Swallowing dysfunction in 101 patients with nephropathic cystinosis: benefit of long-term cysteamine therapy.
    Sonies BC; Almajid P; Kleta R; Bernardini I; Gahl WA
    Medicine (Baltimore); 2005 May; 84(3):137-146. PubMed ID: 15879904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nephropathic cystinosis in children: An overlooked disease.
    Soliman NA; El-Baroudy R; Rizk A; Bazaraa H; Younan A
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):436-42. PubMed ID: 19414947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous cysteamine therapy for nephropathic cystinosis.
    Gahl WA; Ingelfinger J; Mohan P; Bernardini I; Hyman PE; Tangerman A
    Pediatr Res; 1995 Oct; 38(4):579-84. PubMed ID: 8559613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cystinosis : Diagnosis, cystine-depleting therapy, and transition].
    Kaufeld J; Weber LT; Kurschat C; Canaan-Kuehl S; Brand E; Oh J; Pape L
    Internist (Berl); 2018 Aug; 59(8):861-867. PubMed ID: 29671012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Follow-up and treatment of adults with cystinosis in the Netherlands.
    Geelen JM; Monnens LA; Levtchenko EN
    Nephrol Dial Transplant; 2002 Oct; 17(10):1766-70. PubMed ID: 12270982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cystinosin-deficient rats recapitulate the phenotype of nephropathic cystinosis.
    Hollywood JA; Kallingappa PK; Cheung PY; Martis RM; Sreebhavan S; 'Atiola RD; Chatterjee A; Buckels EJ; Matthews BG; Lewis PM; Davidson AJ
    Am J Physiol Renal Physiol; 2022 Aug; 323(2):F156-F170. PubMed ID: 35695380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of long-term cysteamine treatment in patients with cystinosis.
    Ariceta G; Giordano V; Santos F
    Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients.
    Belldina EB; Huang MY; Schneider JA; Brundage RC; Tracy TS
    Br J Clin Pharmacol; 2003 Nov; 56(5):520-5. PubMed ID: 14651726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic challenge in a patient with nephropathic juvenile cystinosis: a case report.
    Higashi S; Matsunoshita N; Otani M; Tokuhiro E; Nozu K; Ito S
    BMC Nephrol; 2017 Sep; 18(1):300. PubMed ID: 28950840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cystinosis in adults: A systemic disease].
    Servais A; Goizet C; Bertholet-Thomas A; Decramer S; Llanas B; Choukroun G; Novo R
    Nephrol Ther; 2015 Jun; 11(3):152-9. PubMed ID: 25769364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.
    Gahl WA; Kuehl EM; Iwata F; Lindblad A; Kaiser-Kupfer MI
    Mol Genet Metab; 2000; 71(1-2):100-20. PubMed ID: 11001803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in the treatment of cystinosis.
    Schneider JA; Clark KF; Greene AA; Reisch JS; Markello TC; Gahl WA; Thoene JG; Noonan PK; Berry KA
    J Inherit Metab Dis; 1995; 18(4):387-97. PubMed ID: 7494398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chitotriosidase as a Novel Biomarker for Therapeutic Monitoring of Nephropathic Cystinosis.
    Veys KRP; Elmonem MA; Van Dyck M; Janssen MC; Cornelissen EAM; Hohenfellner K; Prencipe G; van den Heuvel LP; Levtchenko E
    J Am Soc Nephrol; 2020 May; 31(5):1092-1106. PubMed ID: 32273301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.